Reversal of Tumor Immune Inhibition Using a Chimeric Cytokine Receptor

Molecular Therapy

Volumn 22, Issue 6, 2014, Pages 1211-1220

  Leen, Ann M ^a   Sukumaran, Sujita ^a   Watanabe, Norihiro ^a   Mohammed, Somala ^a   Keirnan, Jacqueline ^a   Yanagisawa, Ryu ^a   Anurathapan, Usanarat ^a   Rendon, David ^a   Heslop, Helen E ^a   Rooney, Cliona M ^a   Brenner, Malcolm K ^a   Vera, Juan F ^a  

^a TEXAS CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHIMERIC PROTEIN; CYTOKINE RECEPTOR; INTERLEUKIN 4; INTERLEUKIN 4 RECEPTOR; INTERLEUKIN 7 RECEPTOR; TUMOR ANTIGEN; HYBRID PROTEIN; INTERLEUKIN 4 RECEPTOR ALPHA;

ADOPTIVE IMMUNOTHERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE ACTIVATION; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PROTEIN DOMAIN; SIGNAL TRANSDUCTION; ADOPTIVE TRANSFER; ANIMAL; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; HEK293 CELL LINE; IMMUNOLOGY; NEOPLASMS, EXPERIMENTAL; SCID MOUSE; T LYMPHOCYTE; TRANSGENE; TRANSPLANTATION; TUMOR CELL LINE; TUMOR MICROENVIRONMENT;

ADOPTIVE TRANSFER; ANIMALS; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HEK293 CELLS; HUMANS; INTERLEUKIN-4 RECEPTOR ALPHA SUBUNIT; LYMPHOCYTE ACTIVATION; MICE, SCID; NEOPLASMS, EXPERIMENTAL; RECEPTORS, INTERLEUKIN-7; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES; TRANSGENES; TUMOR MICROENVIRONMENT; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84902146901     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2014.47     Document Type: Article

References (49)

1. Hinrichs, CS and Rosenberg, SA (2014). Exploiting the curative potential of adoptive T-cell therapy for cancer. Immunol Rev 257: 56-71.
2. Pule, MA, Savoldo, B, Myers, GD, Rossig, C, Russell, HV, Dotti, G et al. (2008). Virusspecific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med 14: 1264-1270.
3. Straathof, KC, Bollard, CM, Popat, U, Huls, MH, Lopez, T, Morriss, MC et al. (2005). Treatment of nasopharyngeal carcinoma with Epstein-Barr virus-specific T lymphocytes. Blood 105: 1898-1904. (Pubitemid 40731770)
4. Bollard, CM, Gottschalk, S, Leen, AM, Weiss, H, Straathof, KC, Carrum, G et al. (2007). Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer. Blood 110: 2838-2845. (Pubitemid 350006936)
5. Bollard, CM, Gottschalk, S, Torrano, V, Diouf, O, Ku, S, Hazrat, Y et al. (2014). Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting epstein-barr virus latent membrane proteins. J Clin Oncol 32: 798-808.
6. Chia, WK, Teo, M, Wang, WW, Lee, B, Ang, SF, Tai, WM et al. (2014). Adoptive T-cell transfer and chemotherapy in the first-line treatment of metastatic and/or locally recurrent nasopharyngeal carcinoma. Mol Ther 22: 132-139.
7. Leen, AM, Rooney, CM and Foster, AE (2007). Improving T cell therapy for cancer. Annu Rev Immunol 25: 243-265. (Pubitemid 46697909)
8. Peggs, KS, Quezada, SA and Allison, JP (2009). Cancer immunotherapy: costimulatory agonists and co-inhibitory antagonists. Clin Exp Immunol 157: 9-19.
9. Rabinovich, GA, Gabrilovich, D and Sotomayor, EM (2007). Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol 25: 267-296. (Pubitemid 46697910)
10. Callahan, MK and Wolchok, JD (2013). At the bedside: CTLA-4-and PD-1-blocking antibodies in cancer immunotherapy. J Leukoc Biol 94: 41-53.
11. Hodi, FS, O'Day, SJ, McDermott, DF, Weber, RW, Sosman, JA, Haanen, JB et al. (2010). Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363: 711-723.
12. Topalian, SL, Hodi, FS, Brahmer, JR, Gettinger, SN, Smith, DC, McDermott, DF et al. (2012). Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366: 2443-2454.
13. Hamid, O, Robert, C, Daud, A, Hodi, FS, Hwu, WJ, Kefford, R et al. (2013). Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 369: 134-144.
14. Bollard, CM, Rössig, C, Calonge, MJ, Huls, MH, Wagner, HJ, Massague, J et al. (2002). Adapting a transforming growth factor beta-related tumor protection strategy to enhance antitumor immunity. Blood 99: 3179-3187. (Pubitemid 34525296)
15. Lacuesta, K, Buza, E, Hauser, H, Granville, L, Pule, M, Corboy, G et al. (2006). Assessing the safety of cytotoxic T lymphocytes transduced with a dominant negative transforming growth factor-beta receptor. J Immunother 29: 250-260. (Pubitemid 44297293)
16. Pangault, C, Amé-Thomas, P, Ruminy, P, Rossille, D, Caron, G, Baia, M et al. (2010). Follicular lymphoma cell niche: identification of a preeminent IL-4-dependent T(FH)-B cell axis. Leukemia 24: 2080-2089.
17. Conticello, C, Pedini, F, Zeuner, A, Patti, M, Zerilli, M, Stassi, G et al. (2004). IL-4 protects tumor cells from anti-CD95 and chemotherapeutic agents via up-regulation of antiapoptotic proteins. J Immunol 172: 5467-5477. (Pubitemid 38542047)
18. Roca, H, Craig, MJ, Ying, C, Varsos, ZS, Czarnieski, P, Alva, AS et al. (2012). IL-4 induces proliferation in prostate cancer PC3 cells under nutrient-depletion stress through the activation of the JNK-pathway and survivin up-regulation. J Cell Biochem 113: 1569-1580.
19. Todaro, M, Alea, MP, Di Stefano, AB, Cammareri, P, Vermeulen, L, Iovino, F et al. (2007). Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. Cell Stem Cell 1: 389-402. (Pubitemid 47506537)
20. Todaro, M, Lombardo, Y, Francipane, MG, Alea, MP, Cammareri, P, Iovino, F et al. (2008). Apoptosis resistance in epithelial tumors is mediated by tumor-cell-derived interleukin-4. Cell Death Differ 15: 762-772. (Pubitemid 351405081)
21. Wurster, AL, Tanaka, T and Grusby, MJ (2000). The biology of Stat4 and Stat6. Oncogene 19: 2577-2584. (Pubitemid 30339213)
22. Faffe, DS, Flynt, L, Bourgeois, K, Panettieri, RA Jr and Shore, SA (2006). Interleukin-13 and interleukin-4 induce vascular endothelial growth factor release from airway smooth muscle cells: role of vascular endothelial growth factor genotype. Am J Respir Cell Mol Biol 34: 213-218. (Pubitemid 43202468)
23. Nelms, K, Keegan, AD, Zamorano, J, Ryan, JJ and Paul, WE (1999). The IL-4 receptor: signaling mechanisms and biologic functions. Annu Rev Immunol 17: 701-738. (Pubitemid 29241138)
24. Jiang, Q, Li, WQ, Hofmeister, RR, Young, HA, Hodge, DR, Keller, JR et al. (2004). Distinct regions of the interleukin-7 receptor regulate different Bcl2 family members. Mol Cell Biol 24: 6501-6513. (Pubitemid 38891148)
25. Barata, JT, Cardoso, AA, Nadler, LM and Boussiotis, VA (2001). Interleukin-7 promotes survival and cell cycle progression of T-cell acute lymphoblastic leukemia cells by down-regulating the cyclin-dependent kinase inhibitor p27(kip1). Blood 98: 1524-1531.
26. Palmada, M, Boehmer, C, Akel, A, Rajamanickam, J, Jeyaraj, S, Keller, K et al. (2006). SGK1 kinase upregulates GLUT1 activity and plasma membrane expression. Diabetes 55: 421-427. (Pubitemid 43343272)
27. Wolchok, JD, Neyns, B, Linette, G, Negrier, S, Lutzky, J, Thomas, L et al. (2010). Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 11: 155-164.
28. Wolchok, JD, Weber, JS, Maio, M, Neyns, B, Harmankaya, K, Chin, K et al. (2013). Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials. Ann Oncol 24: 2174-2180.
29. Denton, CP and Abraham, DJ (2001). Transforming growth factor-beta and connective tissue growth factor: key cytokines in scleroderma pathogenesis. Curr Opin Rheumatol 13: 505-511. (Pubitemid 33070969)
30. Overwijk, WW and Schluns, KS (2009). Functions of C cytokines in immune homeostasis: current and potential clinical applications. Clin Immunol 132: 153-165.
31. Walsh, ST (2012). Structural insights into the common I-chain family of cytokines and receptors from the interleukin-7 pathway. Immunol Rev 250: 303-316.
32. Morrow, MA, Lee, G, Gillis, S, Yancopoulos, GD and Alt, FW (1992). Interleukin-7 induces N-myc and c-myc expression in normal precursor B lymphocytes. Genes Dev 6: 61-70.
33. Grupp, SA, Kalos, M, Barrett, D, Aplenc, R, Porter, DL, Rheingold, SR et al. (2013). Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 368: 1509-1518.
34. Porter, DL, Levine, BL, Kalos, M, Bagg, A and June, CH (2011). Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 365: 725-733.
35. Kalos, M, Levine, BL, Porter, DL, Katz, S, Grupp, SA, Bagg, A et al. (2011). T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 3: 95ra73.
36. Morgan, RA, Yang, JC, Kitano, M, Dudley, ME, Laurencot, CM and Rosenberg, SA. (2010). Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther 18: 843-851.
37. Lamers, CH, Sleijfer, S, van Steenbergen, S, van Elzakker, P, van Krimpen, B, Groot, C et al. (2013). Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity. Mol Ther 21: 904-912.
38. Lamers, CH, Sleijfer, S, Vulto, AG, Kruit, WH, Kliffen, M, Debets, R et al. (2006). Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J Clin Oncol 24: e20-e22.
39. Wilkie, S, van Schalkwyk, MC, Hobbs, S, Davies, DM, van der Stegen, SJ, Pereira, AC et al. (2012). Dual targeting of ErbB2 and MUC1 in breast cancer using chimeric antigen receptors engineered to provide complementary signaling. J Clin Immunol 32: 1059-1070.
40. Kloss, CC, Condomines, M, Cartellieri, M, Bachmann, M and Sadelain, M (2013). Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells. Nat Biotechnol 31: 71-75.
41. Anurathapan, U, Chan, RC, Hindi, HF, Mucharla, R, Bajgain, P, Hayes, BC et al. (2014). Kinetics of tumor destruction by chimeric antigen receptor-modified T cells. Mol Ther 22: 623-633.
42. Hacein-Bey-Abina, S, von Kalle, C, Schmidt, M, Le Deist, F, Wulffraat, N, McIntyre, E et al. (2003). A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 348: 255-256. (Pubitemid 36077924)
43. Hacein-Bey-Abina, S, Von Kalle, C, Schmidt, M, McCormack, MP, Wulffraat, N, Leboulch, P et al. (2003). LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 302: 415-419. (Pubitemid 37296260)
44. Bear, AS, Morgan, RA, Cornetta, K, June, CH, Binder-Scholl, G, Dudley, ME et al. (2012). Replication-competent retroviruses in gene-modified T cells used in clinical trials: is it time to revise the testing requirements? Mol Ther 20: 246-249.
45. Scholler, J, Brady, TL, Binder-Scholl, G, Hwang, WT, Plesa, G, Hege, KM et al. (2012). Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells. Sci Transl Med 4: 132ra53.
46. Rooney, CM, Smith, CA, Ng, CY, Loftin, S, Li, C, Krance, RA et al. (1995). Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet 345: 9-13.
47. Vera, JF, Brenner, LJ, Gerdemann, U, Ngo, MC, Sili, U, Liu, H et al. (2010). Accelerated production of antigen-specific T cells for preclinical and clinical applications using gas-permeable rapid expansion cultureware (G-Rex). J Immunother 33: 305-315.
48. Vera, JF, Hoyos, V, Savoldo, B, Quintarelli, C, Giordano Attianese, GM, Leen, AM et al. (2009). Genetic manipulation of tumor-specific cytotoxic T lymphocytes to restore responsiveness to IL-7. Mol Ther 17: 880-888.
49. Irizarry, RA, Hobbs, B, Collin, F, Beazer-Barclay, YD, Antonellis, KJ, Scherf, U et al. (2003). Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 4: 249-264.